跳至主要内容
临床试验/NCT02133105
NCT02133105已完成3 期

Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure

Göteborg University1 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2014年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
33
试验地点
1
主要终点
Change in glomerular filtration rate

研究概览

简要总结

Although inotropes have a favorable effect on central hemodynamics in patients with heart failure, their effect on renal hemodynamics is incompletely defined. The purpose of this study is to evaluate the efficacy of a 75 min intravenous infusion of levosimendan compared to a 75 min infusion of dobutamine on renal hemodynamics and function in patients with chronic heart failure and signs of cardiorenal syndrome. The investigators hypothesis is that patients treated with levosimendan will show greater increases in renal blood flow and glomerular filtration rate (GFR) than those treated with dobutamine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written, signed and dated informed consent
  • Male and Female subjects ≥18 years of age
  • Chronic congestive heart failure scheduled for right sided cardiac catheterization
  • Left ventricular ejection fraction ≤ 40% determined by echocardiography
  • Elevation of N Terminal-proBNP ≥ 500 ng/L
  • Cardiorenal syndrome (30ml/min ≤ estimated GFR ≤ 80 ml/min (MDRD)

排除标准

  • Acute heart failure, untreated
  • Systolic blood pressure < 80 mmHg
  • Tachycardia above 100 bpm
  • Angina Canadian Cardiovascular Society (CCS) class III or higher
  • Aortic stenosis
  • Hypertrophic cardiomyopathy
  • Restrictive cardiomyopathy
  • The presence of kidney disease diagnosed before heart failure
  • Administration of radiographic contrast < 1 week
  • Radiographic contrast allergy
  • In the Investigator's opinion, the patient has a clinically significant disease that could be adversely affected by study participation

研究组 & 干预措施

Levosimendan

Active Comparator

Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.

干预措施: Levosimendan (Drug)

Dobutamine

Active Comparator

Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.

干预措施: Dobutamine (Drug)

结局指标

主要结局

Change in glomerular filtration rate

时间窗: 75 min minus baseline

Chrome-ethylenediaminetetraacetic acid (EDTA) infusion clearance

Change in renal blood flow

时间窗: 75 min minus baseline

Para-aminohippuric acid (PAH) infusion clearance

次要结局

  • Change in renal vascular resistance(75 min minus baseline)
  • Change in renal oxygen consumption and oxygen extraction(75 min minus baseline)
  • Change in central hemodynamics(75 min minus baseline)
  • Change in filtration fraction(75 min minus baseline)

研究者

发起方
Göteborg University
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验